中国药房2017，Vol.28Issue(26)：3604-3609,6.DOI:10.6039/j.issn.1001-0408.2017.26.02
PAD患者基因多态性与氯吡格雷抗血小板疗效的相关性研究
Study on the Correlation of Gene Polymorphism with Antiplatelet Efficacy of Clopidogrel in PAD Patients
摘要
Abstract
OBJECTIVE:To investigate the correlation of gene polymorphism in peripheral artery disease(PAD)patients with antiplatelet efficacy of clopidogrel. METHODS:Reviewing related domestic and foreign literatures in recent years,the correlation of gene polymorphism in PAD patients with antiplatelet efficacy of clopidogrel was summarized and analyzed. RESULTS&CON-CLUSIONS:At present,a variety of genes associated with clopidogrel antiplatelet efficacy and major adverse cardiovascular events (MACE)have been identified,including cytochrome P450(CYP)2C19,adenosine three phosphate binding cassette B subfamily 1 (ABCB1),paraoxonase 1 (PON1) and adenosine diphosphate P2Y12 receptor (P2Y12),etc. CYP2C19*2,*3 allele may reduce the antiplatelet effect of clopidogrel. Their correlation has been confirmed by a number of studies,and study results are broadly con-sistent. Mutations in the ABCB1 C3435T and PON1 Q192R sites may lead to a lower response to clopidogrel and increase the risk of MACE;but there is a lack of large-scale prospective clinical studies,and the present results are inconsistent. P2Y12 gene poly-morphism in PAD patients has not been found to be significantly associated with clopidogrel efficacy.关键词
外周动脉疾病/氯吡格雷/基因多态性/CYP2C19基因/ABCB1基因/PON1基因/P2Y12基因/抗血小板作用Key words
Peripheral artery disease/Clopidogrel/Gene polymorphism/CYP2C19 gene/ABCB1 gene/PON1 gene/P2Y12 gene/Antiplatelet efficacy分类
医药卫生引用本文复制引用
徐晓宇,林阳,石秀锦,续茜桥..PAD患者基因多态性与氯吡格雷抗血小板疗效的相关性研究[J].中国药房,2017,28(26):3604-3609,6.基金项目
"重大新药创制"科技重大专项(No.2012ZX09303016) （No.2012ZX09303016）
